Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease

Key Takeaways:

• Novo Nordisk is paying up to $5.2 billion to acquire Akero Therapeutics.
• Akero’s late-stage drug targets a life-threatening liver disease.
• The acquisition marks Novo Nordisk’s continued expansion beyond weight-loss medications.
• This deal highlights an ongoing trend of major mergers in the pharmaceutical industry.
• The news was originally reported on October 9, 2025, by Marketwatch.

A Strategic Acquisition

Novo Nordisk, the Danish drugmaker widely recognized for its weight-loss medication Ozempic, has announced its intent to acquire San Francisco-based biotech firm Akero Therapeutics. The purchase could reach a total of $5.2 billion, reflecting the pharmaceutical giant’s commitment to deepening its reach beyond its existing portfolio.

Why Akero Matters

Akero Therapeutics has been developing a late-stage therapy that aims to treat a fatal liver disease, a condition with limited treatment options. By absorbing Akero’s research and potential product pipeline, Novo Nordisk seeks to expand its expertise in a new and critical therapeutic space.

Deal Details

Under the terms of the agreement, Novo Nordisk will pay an initial sum, with the total amount potentially rising to $5.2 billion if key milestones are met. Officials from both companies highlight that the collaboration could bolster the speed and scale of bringing the liver disease drug to market.

Industry Context

Pharmaceutical acquisitions have been on the rise, reflecting growing interest among industry leaders in promising new areas of research. By investing in Akero’s late-stage development program, Novo Nordisk continues this trend while positioning itself at the forefront of potential breakthroughs in serious liver conditions.

Looking Ahead

While Novo Nordisk’s reputation and success are closely tied to its weight-loss treatments, this strategic move underscores the company’s broader objectives. By gaining access to Akero’s research, Novo Nordisk aims to diversify its drug portfolio and offer new solutions for life-threatening diseases.

This news was originally released by Marketwatch on October 9, 2025, signifying a pivotal moment for both companies and the wider healthcare market.